Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

Haemophilia

Volumn 5, Issue SUPPL. 3, 1999, Pages 25-32

  Leissinger, C A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated prothrombin complex concentrates; Antibody; AUTOPLEX T; Haemophilia A; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING INHIBITOR; PROTHROMBIN COMPLEX;

ADVERSE DRUG REACTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTHRITIS; ARTHROPATHY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEMARTHROSIS; HEMOPHILIA; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL MEMORY; MAXIMUM PERMISSIBLE DOSE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

BLOOD COAGULATION FACTORS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; ISOANTIBODIES; THROMBOSIS;

EID: 0032729980     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00034.x     Document Type: Review

References (45)

1. Hay CRM. Factor VIII inhibitors in mild and moderate severity haemophilia A. Haemophilia 1998; 4: 558-63.
2. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-17.
3. Penner JA, Kelly PE. Management of patients with factor VIII or IX inhibitors. Sem Thromb Hemostas 1975; 1: 386-99.
4. Blatt PM, White GC, McMillan CW, Roberts HR. Treatment of anti-factor VIII antibodies. Thromb Haemostas 1977; 38: 514-23.
5. Ekert H, Price DA, Lane JL, Dean FL. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII. Aust NZ J Med 1979; 9: 241-4.
6. Blatt PM, Ménaché D, Roberts HR. A survey of the effectiveness of prothrombin complex concentrates in controlling haemorrhage in patients with haemophilia and antifactor VIII antibodies. Thromb Haemostas 1980; 44: 39-42.
7. Penner JA. Treatment of inhibitor patients with activated prothrombin complex concentrates. Prog Clin Biol Res 1984; 150: 281-308.
8. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 569-73.
9. Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-4.
10. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk van Houwelingen H, van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981; 305: 717-21.
11. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
12. Lusher JM. Controlled clinical trials with prothrombin complex concentrates. Prog Clin Biol Res 1984; 150: 277-90.
13. Eyster ME, Spero JA, Catalano PM, et al. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experiences - 1978-1982. Prog Clin Biol Res 1984; 150: 309-22.
14. Lusher JM, Eyster ME, Hilgartner MW, et al. Panel discussion on the treatment of patients with factor VIII inhibitors. In: Hoyer LW, ed. Factor VIII Inhibitors. New York: Allan R. Liss, Inc., 1984; 323-35.
15. Kreuz W, Escuriola-Ettinghausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-17.
16. Nilsson IM, Berntrop E, Lofqvist T, Pettersson H. Twenty five years' experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32.
17. Hutchinson RJ, Penner JA, Hensinger RN. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy. Pediatrics 1983; 71: 631-3.
18. Yolken RH, Hilgartner MW. Prothrombin complex concentrates: use in treatment of hemophiliacs with factor VIII inhibitors. Am J Dis Child 1978; 132: 291-3.
19. Heisel MA, Gomperts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102: 951-4.
20. Hanna WT, Madigan RR, Miles MA, Lange RD. Activated factor IX complex in treatment of surgical cases of haemophilia A with inhibitors. Thromb Haemost 1981; 46: 638-41.
21. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P, and the members of FEIBA study group. Multicentre retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
22. Buchanan GR, Kevy SV. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics 1978; 62: 767-74.
23. Kelly P, Penner JA. Antihemophilic factor inhibitors: management with prothrombin complex concentrates. JAMA 1976; 236: 2061-4.
24. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 164-7.
25. Abildgaard CF, Penner JA, Watson-Williams J. Antiinhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
26. Bruckmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
27. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Sem Hematol 1991; 28: 3-5.
28. Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A. Laboratory evidence of DIC under FEIBA® treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res 1981; 22: 177-84.
29. Chavin SI, Siegel DM, Rocco TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor III inhibitor. Am J Med 1988; 85: 245-9.
30. Tabor DC, Votaw ML. Fatal myocardial hemorrhagic infarction in hemophilia A and factor IX and Autoplex therapy. Blood 1983; 62: 278A.
31. Gruppo RA, Bove KE, Donaldson VH. Fatal myocardial necrosis associated with prothrombin complex concentrate therapy in hemophilia A. N Engl J Med 1983; 289: 592.
32. Sullivan DW, Purdy LJ, Billingham M, Gladner BE. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics 1984; 74: 279-81.
33. Agrawal BL, Zelkowitz L, Hletko P. Acute myocardial infarction in a young hemophiliac patient during therapy with factor IX concentrate and epsilon-aminocaproic acid. J Pediatr 1981; 98: 931-3.
34. Fuerth JH, Mahrer P. Myocardial infarction after factor IX therapy. JAMA 1981; 245: 1455-6.
35. Schimpf L, Zeltsch CH, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet 1982; II: 1043.
36. Karayalcin G, Goldberg B, Cherrick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8 year old boy with hemophilia A and factor VIII inhibitors. Am J Ped Hematol Oncol 1993; 15: 416-9.
37. Gruen OR, Winchester PH, Brill PW, Ramirez E. Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A. Pediatr Radiol 1977; 27: 271-2.
38. Hilgartner M. Editorial. Pediatrics 1984; 74: 290-1.
39. Kasper CK. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 9: 57-86.
40. Allain JP, Krieger GR. Prothrombin-complex concentrate in treatment of classical haemophilia with factor VIII antibody. Lancet 1975; 2: 1203.
41. Laurian Y, Girma JP, Lambert T, Meyer D, Larrieu MJ. Incidence of immune responses following 102 infusions of Autoplex in 18 hemophilic patients with antibody to factor VIII. Blood 1984; 63: 457-62.
42. Kasper C, The Hemophilia Study Group. Effect of prothrombin complex concentrate on FVIII inhibitor levels. Blood 1979; 54: 1358-68.
43. Kantrowitz JL, Lee ML, McClure DA, Kingdon HS, Thomas WR. Early experience with use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII. Clin Ther 1987; 9: 405-19.
44. Lechner K, Nowotny C, Krinninger B, Zegner M, Deutsch E. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level. Thromb Haemostas (Stuttg) 1978; 40: 478-85.
45. Hilgartner MW, Knatterud GL, FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-8.